ArticleEuropean heart journal open2022
Adherence to statin therapy: it seems we know everything, yet we do nothing.
Article in European heart journal open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial.European heart journal · 2026Trial
- Trial
- Statin prescription patterns among patients with type 2 diabetes mellitus for primary and secondary prevention of cardiovascular disease.BMC endocrine disorders · 2026Article
- Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice.Current atherosclerosis reports · 2026Review
- Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy.Nutrients · 2026Review
- Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease.Journal of the Saudi Heart Association · 2026Article
- Facts and myths about the use and effects of statins in patients with dyslipidaemia: a survey of physicians.Archives of medical science : AMS · 2026Article
- 25 years of lipid-lowering therapy: secular trends in therapy of coronary patients.Wiener klinische Wochenschrift · 2025Observational
- The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!Global heart · 2025Review
- A 360° perspective on cardiovascular prevention: the International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE).Archives of medical science : AMS · 2025Article
- A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY.Theranostics · 2025Article
- Article
- Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study.Journal of the American Heart Association · 2024Article
- Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?Current atherosclerosis reports · 2024Review
- Rhabdomyolysis or Severe Acute Hepatitis Associated with the Use of Red Yeast Rice Extracts: an Update from the Adverse Event Reporting Systems.Current atherosclerosis reports · 2023Review
- A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective.Archives of medical science : AMS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.